image
Healthcare - Biotechnology - NASDAQ - US
$ 0.4441
1.82 %
$ 72.2 M
Market Cap
-0.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TNYA stock under the worst case scenario is HIDDEN Compared to the current market price of 0.444 USD, Tenaya Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TNYA stock under the base case scenario is HIDDEN Compared to the current market price of 0.444 USD, Tenaya Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TNYA stock under the best case scenario is HIDDEN Compared to the current market price of 0.444 USD, Tenaya Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TNYA

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5$0.0$0.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-116 M OPERATING INCOME
11.62%
-111 M NET INCOME
10.44%
-90.5 M OPERATING CASH FLOW
11.34%
1.13 M INVESTING CASH FLOW
-97.68%
47.7 M FINANCING CASH FLOW
1079.28%
0 REVENUE
0.00%
-24.7 M OPERATING INCOME
7.71%
-23.8 M NET INCOME
7.01%
-18.4 M OPERATING CASH FLOW
7.30%
14.1 M INVESTING CASH FLOW
146.86%
377 K FINANCING CASH FLOW
1116.13%
Balance Sheet Tenaya Therapeutics, Inc.
image
Current Assets 67.4 M
Cash & Short-Term Investments 61.4 M
Receivables 0
Other Current Assets 5.93 M
Non-Current Assets 52.6 M
Long-Term Investments 0
PP&E 47.7 M
Other Non-Current Assets 4.82 M
51.23 %4.94 %39.81 %4.02 %Total Assets$119.9m
Current Liabilities 16 M
Accounts Payable 5.16 M
Short-Term Debt 2.78 M
Other Current Liabilities 8.04 M
Non-Current Liabilities 11.1 M
Long-Term Debt 10.8 M
Other Non-Current Liabilities 281 K
19.06 %10.26 %29.66 %39.98 %Total Liabilities$27.1m
EFFICIENCY
Earnings Waterfall Tenaya Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 116 M
Operating Income -116 M
Other Expenses -4.82 M
Net Income -111 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)000(116m)(116m)5m(111m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-119.68% ROE
-119.68%
-92.65% ROA
-92.65%
-108.62% ROIC
-108.62%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tenaya Therapeutics, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)202020202021202120222022202320232024202420252025
Net Income -111 M
Depreciation & Amortization 8.28 M
Capital Expenditures -1.02 M
Stock-Based Compensation 16.5 M
Change in Working Capital -7.93 M
Others -3.58 M
Free Cash Flow -91.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tenaya Therapeutics, Inc.
image
TNYA has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Tenaya Therapeutics, Inc.
image
Sold
0-3 MONTHS
10.6 K USD 3
3-6 MONTHS
4.79 K USD 1
6-9 MONTHS
56.6 K USD 3
9-12 MONTHS
0 USD 0
Bought
132 M USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201;  RNA and Protein Levels Increase Over Time All Cohort 1 Patients with Severe Disease at Baseline Achieved NYHA Class I Two of Three Patients Experienced Improvements in One or More Measures of Hypertrophy Expects to Complete Enrollment of Cohort 2 in 1H25 and to Report Initial Data in 2H25 SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced that interim data from the first three patients enrolled in the company's MyPEAK-1 Phase 1b/2 clinical trial of TN-201 were highlighted in a Late-Breaker presentation at the 2025 American College of Cardiology Scientific Sessions (ACC.25). globenewswire.com - 1 month ago
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the publications of positive preclinical data for TN-201, the company's gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), in Nature Communications. globenewswire.com - 1 month ago
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology's Annual Scientific Session Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 globenewswire.com - 1 month ago
Insiders Are Loading Up on These 4 Biotech Stocks Now Things are heating up in the biotechnology space, with a flurry of recent initial public offerings and some notable insider purchases of the past week or so. 247wallst.com - 1 month ago
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy globenewswire.com - 1 month ago
Tenaya Therapeutics Announces Pricing of Public Offering SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 75,000,000 total units for gross proceeds of approximately $52.5 million prior to deducting underwriting discounts and commissions and offering expenses. globenewswire.com - 1 month ago
Tenaya Therapeutics Announces Proposed Public Offering SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share, Series A warrants and Series B warrants. The pre-funded warrants will be immediately exercisable and will not expire. All of the securities in this offering will be sold by Tenaya. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. globenewswire.com - 2 months ago
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya's Chief Executive Officer, will participate in TD Cowen's 45th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference 2025. Details are as follows: globenewswire.com - 2 months ago
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine Funding will Support Ongoing RIDGE™ -1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy globenewswire.com - 2 months ago
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies  for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy Additional Cohort 1 Data to be Reported in 1H25 Building on Promising Initial Data Initial Data from RIDGE™-1 Phase 1b Clinical Trial of TN-401 for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Expected in 2H25 SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2025. globenewswire.com - 3 months ago
Tenaya Therapeutics price target lowered to $6 from $8 at Leerink Leerink lowered the firm's price target on Tenaya Therapeutics to $6 from $8 and keeps an Outperform rating on the shares after the company announced initial Phase 1b/2 MyPEAK-1 data for TN-201 in MYBPC3-associated hypertrophic cardiomyopathy following program updates in October. The firm notes that while evidence of expression was present, clinical benefit is yet to be determined. Updated Cohort 1 data are expected in the first half of 2025, while initial Cohort 2 and MyClimb natural history data are expected in 2025. https://thefly.com - 4 months ago
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024 Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET globenewswire.com - 4 months ago
8. Profile Summary

Tenaya Therapeutics, Inc. TNYA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 72.2 M
Dividend Yield 0.00%
Description Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Contact 171 Oyster Point Boulevard, South San Francisco, CA, 94080 https://www.tenayatherapeutics.com
IPO Date July 30, 2021
Employees 97
Officers Dr. Eric N. Olson Ph.D. Scientific Founder & Member of Scientific Advisory Board Mr. Tomohiro Higa M.B.A. Senior Vice President of Finance & Interim Principal Accounting Officer Dr. Bruce R. Conklin M.D. Scientific Founder Dr. Sheng Ding Ph.D. Scientific Founder Dr. Saptarsi Haldar M.D. Scientific Founder Mr. Faraz Ali M.B.A. Chief Executive Officer, Interim Principal Financial Officer & Director Dr. Benoit G. Bruneau Ph.D. Scientific Founder Dr. Kee-Hong Kim Ph.D. Chief Technology Officer Ms. Michelle Corral Vice President of Investor Relationship & Corporate Communications Ms. Jennifer Drimmer J.D. General Counsel & Corporate Secretary